|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Acromegaly is a rare disease characterized by high levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).
|
30482010 |
2019 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) levels are the main targets for monitoring acromegaly activity, but they are not in close relationship with the clinical course of the disease and the associated comorbidities.
|
31561638 |
2019 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is associated with increased growth hormone (GH) and insulin-like growth factor-I (IGF-I) secretion which may support tumour development and growth.
|
30742299 |
2019 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pregnancy in acromegaly is safe and is associated with improvements in IGF-1 concentrations.
|
30620709 |
2019 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Insulin-like growth factor-1 (IGF-1) is a thyroid growth factor, and there is a correlation between IGF-1 levels and thyroid volume (TV) in patients with acromegaly.
|
30745501 |
2019 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a rare disease due to chronic excess growth hormone (GH) and IGF-1.
|
30851160 |
2019 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<b>Purpose:</b> Excess growth hormone (GH) secretion in acromegaly patients results in increased levels of IGF-1 expression, which causes the clinical manifestations of acromegaly.
|
30619084 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
GH, IGF-1, and Age Are Important Contributors to Thyroid Abnormalities in Patients with Acromegaly.
|
29593792 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Significant correlation could be detected between insulin-like growth factor 1 (IGF-1) index and peak superior LA-CS (r = .49, P = .05) in acromegaly.
|
29569265 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To evaluate the response of bone to chronic long-term growth hormone (GH) and insulin-like growth factor-1 (IGF1) excess by measuring the expression of selected mRNA and microRNA (miR) in bone tissue samples of patients with active acromegaly.
|
29374071 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated serum IGF-1 level enhances retinal and choroidal thickness in untreated acromegaly patients.
|
29318448 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Beside normal IGF-1 levels, a third of SGHAs displays elevated GH levels and some will eventually progress to acromegaly.
|
29305680 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cabergoline and raloxifene add-on therapy could effectively decrease serum IGF-1 level in patients with inadequately controlled acromegaly.
|
29949429 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As expected, the serum IGF-1 levels were significantly higher in patients with acromegaly than in patients with NFAs and the controls (p < 0.001).
|
29542030 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Regarding operated cases of GH-producing pituitary adenoma, acromegaly clinical manifestations tended to be milder at diagnosis in later years of the decade, and acromegaly was diagnosed at lower IGF-1 levels and in smaller lesions.
|
29113856 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The posterior pharyngeal wall thickness is associated with OSAHS in patients with acromegaly and correlates with IGF-1 levels.
|
29931465 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Acromegaly is a rare disease due to chronic GH excess and to the consequent increase in IGF-1 levels.
|
30034367 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
We present the clinical, radiological and hormonal status of three patients affected by invasive GH-secreting pituitary adenomas without clinical signs and symptoms of acromegaly with elevation of serum IGF-1 from a series of 142 pituitary adenomas operated in our institute with the aid of intraoperative magnetic resonance imaging (MRI).
|
29290044 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Adenoma size and postoperative IGF-1 levels predict surgical outcomes in acromegaly patients: results of the Swiss Pituitary Registry (SwissPit).
|
30141524 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea.
|
29388045 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
IGF-1 results may differ after switching from an older immunoassay to a consensus-compliant assay such as LC-MS. Clinicians should consider the potential impact of assay switching before altering treatment due to discrepant results, particularly in patients monitored over time, such as those with acromegaly and GH deficiency.
|
29218459 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
At last follow up, with an average follow up of 43.2 months, all patients had a reduction in their IGF-1 levels (median IGF-1% upper limit of normal (ULN) baseline: 136% vs last follow up: 97%; p = 0.05); 9 patients (40.9%) were cured, and 4 (18.1%) others demonstrated biochemical control of acromegaly.
|
29429125 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We suggest that IGF-1 levels should be re-evaluated after the improvement of insulin resistance or glycemic regulation for the successful management of patients with acromegaly.
|
29642245 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this review was to investigate the current methods that are being applied to measure and report growth hormone (GH) and insulin-like growth factor-1 (IGF-1) as markers for drug effectiveness in clinical acromegaly research.
|
29605877 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The insulin-like growth factor 1 (IGF-1) levels in the acromegaly patients were linearly and positively correlated with the nose width (<i>p</i> = 0.006) and gonion-gnathion distance (<i>p</i> = 0.029) and linearly and negatively correlated with the nasofrontal angle (<i>p</i> = 0.026).
|
30555420 |
2018 |